NEW YORK, Sept. 7, 2022 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at…


Previous articlePharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX™ Ketamine Patch
Next articleOptimi Health Signs First International Mushroom Supply Agreement with UK-based Avida Global